Niaspan attenuates the adverse effects of bone marrow stromal cell treatment of stroke in type one diabetic rats

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Yan, Tao ^a,b   Ye, Xinchun ^c   Chopp, Michael ^b,d   Zacharek, Alex ^b   Ning, Ruizhuo ^b   Venkat, Poornima ^b,d   Roberts, Cynthia ^b   Lu, Mei ^e   Chen, Jieli ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b HENRY FORD HOSPITAL   (United States)

^c XUZHOU MEDICAL UNIVERSITY   (China)

^d OAKLAND UNIVERSITY   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOGENIN; GELATINASE B; MEMBRANE PROTEIN; NICOTINIC ACID; PHOSPHATE BUFFERED SALINE; PROTEIN ED1; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW STROMAL CELL TRANSPLANTATION; BRAIN ATHEROSCLEROSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL TRANSPLANTATION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INTERNAL CAROTID ARTERY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MONITORING; MONOTHERAPY; NONHUMAN; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TREATMENT DURATION;

ANIMALS; BLOOD-BRAIN BARRIER; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ECTODYSPLASINS; INTRACRANIAL ARTERIOSCLEROSIS; MALE; MATRIX METALLOPROTEINASE 9; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NIACIN; PERMEABILITY; PROTEIN BINDING; PROTEIN TRANSPORT; RATS; RIBONUCLEASE, PANCREATIC; STROKE;

EID: 84896738991     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081199     Document Type: Article

References (59)

1. MEMBERS WG, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, et al. (2010) Heart Disease and Stroke Statistics - 2010 Update: A Report From the American Heart Association. Circulation 121: e46-e215.
2. Idris I, Thomson GA, Sharma JC (2006) Diabetes mellitus and stroke. Int J Clin Pract 60: 48-56. (Pubitemid 43732576)
3. Megherbi S-E, Milan C, Minier D, Couvreur G, Osseby G-V, et al. (2003) Association Between Diabetes and Stroke Subtype on Survival and Functional Outcome 3 Months After Stroke: Data From the European BIOMED Stroke Project. Stroke 34: 688-694. (Pubitemid 36307394)
4. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC (2001) Stress Hyperglycemia and Prognosis of Stroke in Nondiabetic and Diabetic Patients: A Systematic Overview. Stroke 32: 2426-2432. (Pubitemid 32954818)
5. Sacco RL, Wolf PA, Gorelick PB (1999) Risk factors and their management for stroke prevention: outlook for 1999 and beyond. Neurology 53: S15-24. (Pubitemid 29491979)
6. Yong M, Kaste M (2008) Dynamic of Hyperglycemia as a Predictor of Stroke Outcome in the ECASS-II Trial. Stroke 39: 2749-2755.
7. Basu AK, Pal SK, Saha S, Bandyopadhyay R, Mukherjee SC, et al. (2005) Risk factor analysis in ischaemic stroke: a hospital-based study. J Indian Med Assoc 103: 588.
8. Chen J, Zhang ZG, Li Y, Wang L, Xu YX, et al. (2003) Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res 92: 692-699. (Pubitemid 36417705)
9. Chen J, Li Y, Wang L, Zhang Z, Lu D, et al. (2001) Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 32: 1005-1011. (Pubitemid 32285175)
10. Hamano K, Li TS, Kobayashi T, Kobayashi S, Matsuzaki M, et al. (2000) Angiogenesis induced by the implantation of self-bone marrow cells: a new material for therapeutic angiogenesis. Cell Transplant 9: 439-443. (Pubitemid 30655695)
11. Zacharek A, Chen J, Cui X, Li A, Li Y, et al. (2007) Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke. J Cereb Blood Flow Metab 27: 1684-1691. (Pubitemid 47476100)
12. Li Y, Chen J, Wang L, Lu M, Chopp M (2001) Treatment of stroke in rat with intracarotid administration of marrow stromal cells. Neurology 56: 1666-1672. (Pubitemid 32574564)
13. Lu D, Mahmood A, Wang L, Li Y, Lu M, et al. (2001) Adult bone marrow stromal cells administered intravenously to rats after traumatic brain injury migrate into brain and improve neurological outcome. Neuroreport 12: 559-563. (Pubitemid 32173965)
14. Chen J, Ye X, Yan T, Zhang C, Yang X-P, et al. (2011) Adverse Effects of Bone Marrow Stromal Cell Treatment of Stroke in Diabetic Rats. Stroke 42: 3551-3558.
15. Rosenson RS (2003) Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 171: 87-96.
16. Meyers CD, Kamanna VS, Kashyap ML (2004) Niacin therapy in atherosclerosis. Curr Opin Lipidol 15: 659-665. (Pubitemid 39612984)
17. Ye X, Chopp M, Cui X, Zacharek A, Cui Y, et al. (2011) Niaspan enhances vascular remodeling after stroke in type 1 diabetic rats. Exp Neurol 232: 299-308.
18. Chen J, Cui X, Zacharek A, Jiang H, Roberts C, et al. (2007) Niaspan increases angiogenesis and improves functional recovery after stroke. Ann Neurol 62: 49-58. (Pubitemid 47235280)
19. Yan T, Chopp M, Ye X, Liu Z, Zacharek A, et al. (2012) Niaspan increases axonal remodeling after stroke in type 1 diabetes rats. Neurobiol Dis 46: 157-164.
20. Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, et al. (2000) Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. Jama 284: 1263-1270.
21. Ye X, Chopp M, Liu X, Zacharek A, Cui X, et al. (2011) Niaspan reduces high-mobility group box 1/receptor for advanced glycation endproducts after stroke in type-1 diabetic rats. Neuroscience 190: 339-345.
22. Chen J, Sanberg PR, Li Y, Wang L, Lu M, et al. (2001) Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 32: 2682-2688. (Pubitemid 33055324)
23. Hernandez TD, Schallert T (1988) Seizures and recovery from experimental brain damage. Exp Neurol 102: 318-324. (Pubitemid 19005595)
24. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, et al. (1990) A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 10: 290-293. (Pubitemid 20096202)
25. Ho TK, Rajkumar V, Black CM, Abraham DJ, Baker DM (2006) Increased angiogenic response but deficient arteriolization and abnormal microvessel ultrastructure in critical leg ischaemia. Br J Surg 93: 1368-1376. (Pubitemid 44736087)
26. Davalos A, Castillo J, Alvarez-Sabin J, Secades JJ, Mercadal J, et al. (2002) Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 33: 2850-2857. (Pubitemid 35462855)
27. Cohen DM, Patel CB, Ahobila-Vajjula P, Sundberg LM, Chacko T, et al. (2009) Blood-spinal cord barrier permeability in experimental spinal cord injury: dynamic contrast-enhanced MRI. NMR Biomed 22: 332-341.
28. Chen J, Cui X, Zacharek A, Cui Y, Roberts C, et al. (2011) White Matter Damage and the Effect of Matrix Metalloproteinases in Type 2 Diabetic Mice After Stroke. Stroke 42: 445-452.
29. Lawther BK, Kumar S, Krovvidi H (2011) Blood-brain barrier. Continuing Education in Anaesthesia, Critical Care & Pain 11: 128-132.
30. Maier CM, Hsieh L, Yu F, Bracci P, Chan PH (2004) Matrix Metalloproteinase-9 and Myeloperoxidase Expression: Quantitative Analysis by Antigen Immunohistochemistry in a Model of Transient Focal Cerebral Ischemia. Stroke 35: 1169-1174. (Pubitemid 38543538)
31. Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, et al. (1999) Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 878: 212-227. (Pubitemid 29353573)
32. Montaner J, Alvarez-Sabín J, Molina C, Anglés A, Abilleira S, et al. (2001) Matrix Metalloproteinase Expression After Human Cardioembolic Stroke: Temporal Profile and Relation to Neurological Impairment. Stroke 32: 1759-1766. (Pubitemid 32772204)
33. Lucivero V, Prontera M, Mezzapesa DM, Petruzzellis M, Sancilio M, et al. (2007) Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke. Neurological Sciences 28: 165-170. (Pubitemid 47263834)
34. Strydom DJ (1998) The angiogenins. Cell Mol Life Sci 54: 811-824.
35. Gao X, Xu Z (2008) Mechanisms of action of angiogenin. Acta Biochim Biophys Sin (Shanghai) 40: 619-624. (Pubitemid 352009084)
36. Hu G, Riordan JF, Vallee BL (1994) Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci U S A 91: 12096-12100. (Pubitemid 24368611)
37. Tello-Montoliu A, Marin F, Patel J, Roldan V, Mainar L, et al. (2007) Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. Eur Heart J 28: 3006-3011. (Pubitemid 350262264)
38. Soncin F (1992) Angiogenin supports endothelial and fibroblast cell adhesion. Proc Natl Acad Sci U S A 89: 2232-2236.
39. Patel JV, Sosin M, Gunarathne A, Hussain I, Davis RC, et al. (2008) Elevated angiogenin levels in chronic heart failure. Ann Med 40: 474-479.
40. Ozaki H, Hayashi H, Oshima K (1996) Angiogenin levels in the vitreous from patients with proliferative diabetic retinopathy. Ophthalmic Res 28: 356-360. (Pubitemid 27051149)
41. Burgmann H, Hollenstein U, Maca T, Zedwitz-Liebenstein K, Thalhammer F, et al. (1996) Increased serum laminin and angiogenin concentrations in patients with peripheral arterial occlusive disease. J Clin Pathol 49: 508-510. (Pubitemid 26226545)
42. Malamitsi-Puchner A, Sarandakou A, Dafogianni C, Tziotis J, Bartsocas CS (1998) Serum angiogenin levels in children and adolescents with insulin-dependent diabetes mellitus. Pediatr Res 43: 798-800. (Pubitemid 28243651)
43. Chiarelli F, Pomilio M, Mohn A, Tumini S, Verrotti A, et al. (2002) Serum angiogenin concentrations in young patients with diabetes mellitus. Eur J Clin Invest 32: 110-114. (Pubitemid 36232731)
44. Rosenberg GA (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. The Lancet Neurology 8: 205-216.
45. Huang J, Upadhyay UM, Tamargo RJ (2006) Inflammation in stroke and focal cerebral ischemia. Surg Neurol 66: 232-245. (Pubitemid 44279808)
46. Emsley HC, Tyrrell PJ (2002) Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab 22: 1399-1419. (Pubitemid 35424925)
47. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, et al. (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363: 1439-1441. (Pubitemid 38586721)
48. Schurgers E, Kelchtermans H, Mitera T, Geboes L, Matthys P (2010) Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther 12: R31.
49. Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Alwayn IP, et al. (2009) Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 87: 896-906.
50. Bruckert E, Labreuche J, Amarenco P (2010) Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210: 353-361.
51. Montecucco F, Quercioli A, Dallegri F, Viviani GL, Mach F (2010) New evidence for nicotinic acid treatment to reduce atherosclerosis. Expert Rev Cardiovasc Ther 8: 1457-1467.
52. Lukasova M, Malaval C, Gille A, Kero J, Offermanns S (2011) Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 121: 1163-1173.
53. Carlson LA (2004) Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract 58: 706-713.
54. Kamanna VS, Vo A, Kashyap ML (2008) Nicotinic acid: recent developments. Curr Opin Cardiol 23: 393-398. (Pubitemid 351787106)
55. Lee JM, Robson MD, Yu LM, Shirodaria CC, Cunnington C, et al. (2009) Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 54: 1787-1794.
56. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML (2009) Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 202: 68-75.
57. Sunderkötter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C (1994) Macrophages and angiogenesis. Journal of Leukocyte Biology 55: 410-422. (Pubitemid 24097250)
58. Lucas SM, Rothwell NJ, Gibson RM (2006) The role of inflammation in CNS injury and disease. Br J Pharmacol 147 Suppl 1: S232-240. (Pubitemid 43077281)
59. Park CH, Shin TK, Lee HY, Kim SJ, Lee WS (2011) Matrix metalloproteinase inhibitors attenuate neuroinflammation following focal cerebral ischemia in mice. Korean J Physiol Pharmacol 15: 115-122.